Similar studies, such as that by Deng et al. [9], have shown the efficacy of BTK inhibitors (BTKi) like zanubrutinib combined with R-CHOP or rituximab plus lenalidomide (R2) in MYD88-mutated DLBCL, further supporting our findings. Here, BTK is linked to diffuse large B-cell lymphoma.